A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer
Epistemonikos ID: c53ce05aba1024f7a2b95fbdbe99f7b906b2bea2
First added on: May 15, 2024